Prior exposure to fumaric acid esters does not impact on subsequent treatment response to guselkumab
- PMID: 38282352
- DOI: 10.1093/bjd/ljae036
Prior exposure to fumaric acid esters does not impact on subsequent treatment response to guselkumab
Conflict of interest statement
Conflicts of interest N.K. has received honoraria from AbbVie, Janssen, Lilly, Novartis and UCB, and has acted as a subinvestigator in clinical trials for AbbVie, MoonLake and UCB. B.K. has received research support from/was a principal investigator (clinical trials) for AbbVie, Almirall, Janssen, Merck Sharp & Dohme, Novartis, Pfizer and UCB; has been a consultant for AbbVie, Almirall, Celgene, Janssen, Merck Sharp & Dohme, MoonLake, Novartis, Pfizer and UCB; has received honoraria from AbbVie, Almirall, Celgene, Janssen, Lilly, MoonLake, Novartis, Pfizer and UCB; and has been on scientific advisory boards for AbbVie, Almirall, Celgene, Janssen, Lilly, MoonLake, Novartis, Pfizer and UCB.
Comment on
-
Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS).Br J Dermatol. 2024 Jun 20;191(1):36-48. doi: 10.1093/bjd/ljad523. Br J Dermatol. 2024. PMID: 38133615 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources